DGX Q1 FY2026 Earnings: Volume +10.9% vs Revenue per Test -1.3%

Quest Diagnostics reported Q1 2026 revenue of $2.90 billion — up 9.2% year-over-year. How much of that was units, how much was price, and how much was mix? The 10-Q filed April 22, 2026 decomposes it bluntly: volume +10.9%, revenue per requisition -1.30%, with roughly 7 percentage points of organic volume from Fresenius Medical Care and Corewell Health. Excluding those two contracts, organic volume grew only 3.8%. The segment footnote adds a second reveal: DIS operating margin expanded only 15 basis points (one basis point = 0.01 percentage point) while consolidated operating margin expanded 73 basis points — a gap driven almost entirely by an $11 million reduction in general corporate overhead. A third reveal: equity-method investee earnings collapsed from $18 million to $4 million, a silent ~$0.10 per share drag not in management's adjusted-EPS bridge.

Unit Economics: Decomposing the 9.2% Revenue Growth

The growth walk the prepared remarks offered and the 8-K did not: total revenue was up 9.2% year-over-year; volume was up 10.9%; revenue per requisition was down 1.30%. The math of those three numbers says mix and pricing together shaved 1.7 percentage points off a 10.9% volume tailwind, producing the 9.2% consolidated figure. The more consequential decomposition sits one layer down.

"Our total volume, measured by the number of requisitions, increased 10.9% versus the first quarter of 2025, with organic volume up by 10.8%. Fresenius Medical Care and Corewell Health contributed approximately 7% to organic volume growth in the quarter. Our organic volume growth in the quarter was 3.8% excluding the favorable impact from these two relationships. As expected, Fresenius Medical Care and Corewell Health's business mix impacted total revenue per requisition, which was down 1.30% compared to the prior year."

The -1.30% revenue-per-requisition figure is the deliberate cost of two high-volume contract wins. Dialysis and hospital-outsourced panels carry a higher share of routine tests than Quest's advanced diagnostics mix. The 9.2% consolidated growth decomposes to roughly 3.8 points of underlying clinical organic volume, ~5.4 points of Fresenius/Corewell contract-driven volume, offset by ~1.3 points of mix-driven price drag. Once those contracts anniversary, the 9%+ growth rate depends on whether the underlying 3.8% accelerates or a new large contract lands.

The Corewell Health relationship in particular is now more than a contract. The 10-Q's Results of Operations section discloses that the Michigan joint venture signed in August 2025 closed during January 2026, and Quest obtained a controlling 51% interest in the contributed Corewell laboratory business.

"During August 2025, we and Corewell Health signed a definitive agreement to form a new entity which will perform laboratory testing in the state of Michigan via a new laboratory facility. The parties completed the transaction during January 2026... Equity ownership of the newly formed entity is shared 51% by us and 49% by Corewell Health and we are consolidating the entity in our consolidated financial statements. The business is included in our DIS segment."

Because the JV is consolidated, Corewell's lab revenue flows through the top line; the 49% minority interest ($12 million Q1 2026 vs $15 million Q1 2025) runs through noncontrolling interest.

Segment Margin: The 58-Basis-Point Gap Between Reported and Underlying

The consolidated operating-margin print — 13.78% versus 13.05% a year ago, an expansion of 73 basis points — is the single number that dominates a passive read of this quarter. The segment footnote splits it cleanly and shows something different. DIS segment operating income rose from $414 million on $2,589 million of revenue to $457 million on $2,832 million — a segment operating margin of 16.14% versus 15.99%, an expansion of 15 basis points on 9.4% segment revenue growth.

The 58-basis-point gap between DIS segment (+15 bps) and consolidated (+73 bps) operating-margin expansion is driven by the $11 million decline in general corporate activities expense (-14.5%) plus smaller non-operating shifts. On an adjusted basis — CFO Sam Samad's preferred frame — operating margin rose only 10 basis points, from 15.3% to 15.4%. That is essentially flat. The adjusted line reconciles to the DIS segment trajectory more closely than the reported line does.

"Reported operating income in the first quarter was $399 million, or 13.8% of revenues, compared to $346 million, or 13.0% of revenues last year. On an adjusted basis, operating income was $447 million, or 15.4% of revenues, compared to $406 million, or 15.3% of revenues last year. This increase in operating income was primarily due to organic revenue growth and increased productivity, partially offset by the impact of wage increases and, to a lesser extent, weather."

Two retail implications. First, the +73-basis-point consolidated margin print should be qualified — the DIS segment itself delivered only +15 basis points on +9.4% revenue; most of the gap came from $11 million lower general corporate overhead. Second, the equity-method investee collapse ($18M → $4M, –$14M pretax, ~$0.10 per diluted share after the 25.5% adjustment rate) sits entirely below the operating line and is absent from management's margin narrative. The 8-K non-GAAP reconciliation note (c) attributes the drop to carrying-value losses on strategic investments — excluded from adjusted EPS ($2.50, +13.1%) but carried in GAAP EPS ($2.24, +15.5%). Held at prior-year levels, the underlying EPS growth rate would be closer to 20–21%.

How DGX Stacks Against Peers

DGX sits at the scale leader / middle-of-the-pack margin end of a diagnostics peer set that splits into three groups: clinical-lab commodities (LabCorp), specialty diagnostics (Hologic, IDEXX), and high-growth unprofitable specialty (Exact Sciences, Natera). The comparison table below pulls trailing-twelve-month data from MetricDuck's compare_companies endpoint.

Against LabCorp — the only direct clinical-lab competitor at scale — DGX trades at a valuation discount with better margins and returns. LH revenue is 24% larger ($13.95B vs $11.28B), but DGX operating margin (14.27%) is 435 basis points ahead of LH (9.92%), DGX ROIC (8.95%) is 156 basis points ahead of LH (7.39%), and DGX's P/E (21.37x) is below LH's (23.83x). On the specialty side, DGX's 14.27% operating margin is roughly half of Hologic's 17.48% and less than half of IDEXX's 31.60% — a structural feature of the clinical-lab throughput model, where gross margin is capped in the low 30% range versus 50-70% for specialty diagnostics. Against the growth cohort, DGX's 11.03% trailing revenue growth is less than half of Exact Sciences (17.69%) or Natera (35.90%), but DGX produces positive operating income and $1.33 billion of trailing free cash flow while EXAS (-6.35% operating margin, -4.13% ROIC) and NTRA (-13.44% operating margin, -17.28% ROIC) are both loss-making.

Three peer-relative takeaways frame the quarter for a shareholder. First, DGX's P/E of 21.37x embeds a modest growth premium over LH (23.83x is slightly higher only because LH's earnings are more compressed — operating margin 9.92%), but a sharp discount to specialty peers (IDXX 51.33x, HOLX 30.79x). Second, DGX's 8.95% ROIC ranks #2 among the six-name peer set (behind only IDXX at 52.62%), consistent with a mature-lab thesis that generates above-cost-of-capital returns without the capital-light economics of specialty diagnostics. Third, DGX's 2.44x net-debt-to-EBITDA is in line with LH (2.30x) and above the specialty cohort (HOLX 0.73x, IDXX 0.24x); the elevated leverage is not an outlier for clinical-lab operators, but it does constrain buyback urgency versus the asset-light comps. Revenue 3-year CAGR of 5.51% is the most honest statement of the underlying clinical-lab growth base before the Fresenius/Corewell contract wave inflected the 2025-2026 figure.

Peers: LH, HOLX, IDXX, EXAS, NTRA (selected by business-model overlap) — source: agent.

What This Means for DGX Shareholders

The retail reading: DGX delivered a headline beat (revenue +9.2%, adjusted EPS +13.1%) and a guidance raise, but the 10-Q shows the growth is a volume-for-price trade carried largely by two contracts, the underlying segment margin expansion is a narrow 15 basis points, and a hidden $0.10 per share drag on GAAP EPS from strategic-investment carrying-value losses is not in the adjusted-EPS walk. The adjusted EPS number management highlights ($2.50, +13.1%) strips that drag out; the GAAP number ($2.24, +15.5%) embeds it. Both are true.

For a shareholder, the peer-relative take is specific: DGX's 21.37x P/E is below LabCorp's 23.83x despite ROIC 156 basis points higher and operating margin 435 basis points higher. Against specialty peers (IDXX at 51.33x), DGX trades at less than half the multiple — a structural feature of clinical-lab throughput economics, not a mispricing. The guidance raise (+$0.13 at the adjusted EPS midpoint) is underwritten by the Q1 beat and explicitly excludes M&A. Analyst price targets from Baird ($229), Truist ($225), UBS ($220), and Evercore/Jefferies ($225) cluster above the current $204.00 stock (per Benzinga/Markets Daily, April 22-23, 2026).

The prepared-remarks competitive posture is partnership-led: Corewell (hospital), Fresenius (dialysis), City of Hope (Haystack MRD), Google Gemini (Quest AI Companion) all fit a volume-via-collaboration strategy with no competitor named. AI tools delivered a stated 40% customer-service productivity gain; the AI Companion logged ~350,000 patient engagements. Project Nova, the order-to-cash overhaul, targets fall 2027 for the first implementation wave — outside the FY2026 modeling horizon but worth monitoring for scope changes.

Not investment advice — analysis of SEC filings, earnings calls, and press releases.

Frequently Asked Questions

What did Quest Diagnostics (DGX) report for Q1 2026 earnings?

Quest Diagnostics reported Q1 2026 revenue of $2.90 billion (+9.2% year-over-year, +3.2% sequentially), reported diluted EPS of $2.24 (+15.5%), and adjusted diluted EPS of $2.50 (+13.1%). Operating income was $399 million at a 13.78% reported operating margin (+73 basis points year-over-year). Management raised full-year 2026 guidance to revenue of $11.78 billion to $11.90 billion (+6.8% to +7.8%) and adjusted diluted EPS of $10.63 to $10.83, up from a prior range of $10.50 to $10.70. Source: DGX 10-Q filed April 22, 2026 (accession 0001022079-26-000043) and 8-K earnings release filed April 21, 2026.

Why was DGX revenue per requisition down 1.30% year-over-year?

CFO Sam Samad's prepared remarks attributed the 1.30% year-over-year decline in total revenue per requisition to business mix from two contracts. Fresenius Medical Care (end-stage renal disease lab testing) and Corewell Health (Collaborative Lab Solutions in Michigan) together contributed approximately 7 percentage points of the 10.8% organic volume growth in the quarter, and both relationships carry a higher proportion of routine tests than Quest's broader clinical mix. Excluding the mix impact from these two contracts, total revenue per requisition for the clinical business rose approximately 2.5% and unit-price reimbursement was relatively flat. Source: DGX Q1 FY2026 prepared remarks (8-K exhibit, filed 2026-04-21).

How much of DGX's growth was organic excluding Fresenius and Corewell?

Total volume grew 10.9% year-over-year; organic volume grew 10.8%. Per CFO Sam Samad's prepared remarks, Fresenius Medical Care and Corewell Health together contributed approximately 7 percentage points of the organic volume growth, meaning organic volume excluding those two relationships grew approximately 3.8%. Applied to consolidated revenue growth of 9.2%, the decomposition suggests roughly 3.8 percentage points came from underlying-clinical organic volume and the remaining ~5.4 percentage points came from the combination of Fresenius/Corewell volume (partly offset by the -1.30% revenue-per-requisition drag from their routine-test mix). Source: DGX Q1 FY2026 prepared remarks.

Why did DGX's operating margin expand 73 basis points but segment margin only 15 basis points?

Reported consolidated operating margin rose 73 basis points year-over-year to 13.78%, but the Diagnostic Information Services (DIS) segment — which accounts for more than 97% of revenues — expanded operating margin only 15 basis points to 16.14% (from 15.99%). The 58-basis-point gap was driven by general corporate activities expense declining from $76 million to $65 million (a $11 million / -14.5% reduction) and by non-operating line-item shifts. On an adjusted basis, CFO Sam Samad disclosed that adjusted operating margin rose only 10 basis points (15.4% vs 15.3%) — essentially flat. Source: DGX Q1 FY2026 10-Q footnote_segment.

Why did DGX's operating cash flow decline 11.5% year-over-year?

Operating cash flow was $278 million in Q1 2026 versus $314 million in Q1 2025 — a $36 million / 11.5% decrease. The 10-Q attributes the decline to "the timing of operating receipts and disbursements and higher bonus payments in the current period versus a year ago, partially offset by increased operating income." Days sales outstanding were stable at 48 days (up one day from 47 in Q1 2025), so the receivables build is volume-driven rather than a collections issue. Management's full-year 2026 guidance assumes operating cash flow of approximately $1.75 billion, which requires sequential recovery through Q2-Q4 since $278 million annualizes to $1.11 billion. Source: DGX Q1 FY2026 10-Q MD&A Liquidity.

What happened to DGX's equity-method investee earnings in Q1 2026?

Equity in earnings of equity-method investees dropped from $18 million in Q1 2025 to $4 million in Q1 2026 — a $14 million / 77.8% decline on a pretax basis. Net of the 25.5% statutory tax rate management used for adjustments, the drag is roughly $11 million after tax, equivalent to approximately $0.10 per diluted share on 141 million diluted shares outstanding. The 10-Q footnote reconciliation discloses the number. The Q1 2026 earnings release adds context in note (c): the drop includes pretax losses associated with changes in the carrying value of strategic investments. Management excluded these losses from adjusted EPS (which grew 13.1% to $2.50), but they flow through to GAAP EPS (which grew 15.5% to $2.24). The drag was not addressed in the prepared remarks. Source: DGX Q1 FY2026 10-Q footnote_segment and 8-K non-GAAP reconciliation.

How does DGX compare to LabCorp (LH) and specialty diagnostics peers?

Against LabCorp Holdings (LH) — the only clinical-lab peer at scale — DGX trades at a valuation discount with better margins and returns: revenue $11.28 billion vs $13.95 billion, operating margin 14.27% vs 9.92%, ROIC 8.95% vs 7.39%, P/E 21.37x vs 23.83x. Against specialty peers, DGX's lab-throughput model structurally produces lower gross margins (33.2%) than Hologic (51.47% gross margin, 17.48% operating margin) or IDEXX Laboratories (61.80% gross margin, 31.60% operating margin, 52.62% ROIC). Against growth peers, DGX's 11.03% trailing-twelve-month revenue growth is less than half of Exact Sciences (17.69%) or Natera (35.90%), but DGX delivers positive operating income and $1.33 billion of trailing free cash flow while EXAS and NTRA are both loss-making. Source: MetricDuck compare_companies.

What is DGX's Corewell Health joint venture and when did it close?

Quest Diagnostics and Corewell Health signed a definitive agreement in August 2025 to form a new entity to perform laboratory testing in Michigan through a new laboratory facility. The transaction closed in January 2026. Corewell contributed a laboratory business and Quest obtained a controlling financial interest; equity ownership is shared 51% by Quest and 49% by Corewell Health. Quest consolidates the entity in its financial statements and includes the business in the DIS segment. The new laboratory facility is scheduled to be operational during 2027; until then, the parties continue to serve Michigan providers through existing patient service centers and laboratories operated by the new entity. Corewell's revenue contribution is part of the ~7 percentage points of organic volume growth attributed to the Fresenius/Corewell pair in Q1. Source: DGX Q1 FY2026 10-Q MD&A Results of Operations.

Did DGX raise guidance and by how much?

Yes. Quest raised full-year 2026 revenue guidance to $11.78 billion to $11.90 billion (growth of 6.8% to 7.8%) and adjusted diluted EPS guidance to $10.63 to $10.83 — up from a prior range of $10.50 to $10.70. Reported diluted EPS guidance was set at $9.58 to $9.78. Management also affirmed full-year operating cash flow of approximately $1.75 billion, capital expenditures of approximately $550 million, and share count and interest expense consistent with 2025. The guidance explicitly excludes any contribution from prospective M&A. Analyst price-target updates following the print included Baird raising to $229, Truist to $225, UBS to $220, and reiterations at $225 from Evercore and Jefferies (per Benzinga and Markets Daily reporting, April 22-23, 2026). Source: DGX Q1 FY2026 prepared remarks and third-party financial media.

What is DGX's capital return posture after the Q1 2026 dividend increase?

The Q1 2026 quarterly cash dividend was $0.86 per share, up from $0.80 per share in each quarter of 2025 — a 7.5% year-over-year dividend increase. Dividends paid in Q1 2026 were $95 million. On the buyback side, Quest's board authorized an additional $1.0 billion of share repurchases in February 2026, bringing available authorization to $1.4 billion as of March 31, 2026 with no expiration. Zero shares were repurchased in Q1 2026, and zero shares were repurchased in Q1 2025. Trailing-twelve-month capital return was $363 million, entirely dividends, for a capital-return-to-net-income ratio of 27.38%. The 10-Q confirms the posture: dividend-led, with a fully-available buyback authorization that management has not activated in the two most recent comparable quarters. Source: DGX Q1 FY2026 10-Q MD&A Liquidity.

Methodology

This quarterly analysis is based on primary-source SEC filings and the MetricDuck filing intelligence pipeline. Specifically:

• Primary filing: DGX 10-Q for fiscal Q1 2026, filed April 22, 2026 (accession 0001022079-26-000043), covering the quarter ended March 31, 2026. Sections read: mda_results_operations, mda_liquidity, footnote_segment.
• Earnings release: DGX 8-K earnings release filed April 21, 2026 (accession 0001022079-26-000040), including the prepared-remarks PDF exhibit (CEO Jim Davis and CFO Sam Samad) and the non-GAAP reconciliation tables.
• Earnings call: The Q&A portion of the April 21, 2026 earnings call was not filed as an 8-K exhibit; Quest Diagnostics publishes prepared remarks but does not file the Q&A transcript. Verbatim analyst-exchange quotes are therefore unavailable in this article, and quotations from the call are sourced from the prepared-remarks PDF only.
• Peer comparison: Trailing-twelve-month metrics for LH, HOLX, IDXX, EXAS, NTRA pulled from the MetricDuck compare_companies endpoint. The peer set was agent-selected to overlay clinical-lab scale (LH), specialty diagnostics margin benchmark (HOLX, IDXX), and high-growth diagnostics specialty (EXAS, NTRA). MetricDuck's auto-peers (BDX, AKTX, VRNA, ZTS) were rejected because none operate clinical-diagnostics labs.
• Computed metrics: Segment operating margin walks, the 58-basis-point consolidated-vs-segment gap, the ~$0.10 per share equity-method investee drag, and the unit-economics decomposition were computed from the source filings using MetricDuck's filing intelligence pipeline.
• Original data markers: Segment decomposition, the DIS vs consolidated margin gap, and the equity-method investee EPS drag are MetricDuck-original computations not present in the 8-K earnings release or prepared remarks.
• Third-party references: Analyst price-target updates (Baird, Truist, UBS, Evercore, Jefferies) and consensus aggregation are sourced from Benzinga and Markets Daily reporting dated April 22-23, 2026; the MarketBeat aggregate consensus target of $212.23 is cited where relevant.
• Limitations: This analysis is based on MetricDuck's automated extraction of SEC filings and third-party financial media. Numbers are reported as filed; small rounding differences may exist versus the company's own presentation. The Q1 2026 earnings-call Q&A transcript is unavailable and may contain additional analyst pushbacks or management nuance not captured here.

Disclaimer: This article is for informational purposes only and is not investment advice, a recommendation to buy or sell any security, or a solicitation. MetricDuck Research is not a registered investment adviser. All data is sourced from SEC filings, earnings calls, and public financial media; readers should conduct their own research and consult a licensed financial professional before making investment decisions.

Not investment advice — analysis of SEC filings, earnings calls, and press releases.